Cardiac or central nervous system toxicity may result when standard lidocaine doses are administered to patients with circulatory failure. This may be due to the following reason:
**Core Concept**
Lidocaine is a class Ib anti-arrhythmic medication that works by blocking sodium channels in the heart. In patients with circulatory failure, the liver's ability to metabolize lidocaine is impaired, leading to increased plasma levels and potential toxicity.
**Why the Correct Answer is Right**
The correct answer is related to the pharmacokinetics of lidocaine. In patients with circulatory failure, the liver's ability to metabolize lidocaine is impaired due to reduced blood flow and oxygen delivery. This leads to decreased clearance of lidocaine, resulting in increased plasma levels and potential toxicity. Lidocaine is primarily metabolized by the liver enzyme CYP1A2, and alterations in liver blood flow can significantly affect its metabolism.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to the question. The metabolism of lidocaine is not significantly affected by kidney function.
**Option B:** This option is incorrect because lidocaine is primarily metabolized by the liver, not the kidneys.
**Option C:** This option is not directly related to the question. The effect of circulatory failure on lidocaine levels is due to impaired liver metabolism, not the drug's mechanism of action.
**Clinical Pearl / High-Yield Fact**
In critically ill patients, it is essential to consider the potential for altered pharmacokinetics and pharmacodynamics when selecting medications, including anti-arrhythmics like lidocaine.
**Correct Answer:** None of the above options are correct.